Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma

Cancer

Volumn 119, Issue 16, 2013, Pages 2973-2980

  Olivatto, Luis O ^a   Vieira, Fernando M ^a   Pereira, Bruno V ^a   Victorino, Ana P ^a   Bezerra, Marcos ^a   Araujo, Carlos M ^a   Erlich, Felipe ^a   Faroni, Lilian ^a   Castro, Leonaldson ^a   Lusis, Edward C ^a   Marins, Alessandra ^a   Ferreira, Carlos Gil ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

5 fluorouracil; cetuximab; chemoradiation; cisplatin; locally advanced anal canal carcinoma

Indexed keywords

ANTICOAGULANT AGENT; CETUXIMAB; CIPROFLOXACIN; CISPLATIN; FLUOROURACIL; LOPERAMIDE;

ADULT; ADVANCED CANCER; AGED; ANUS CARCINOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLISM; FAINTNESS; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN CELL; HYPERSENSITIVITY; HYPOKALEMIA; HYPONATREMIA; INFECTION; LUNG EMBOLISM; MALE; NEUTROPENIA; OPEN STUDY; PAIN; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE; THROMBOSIS; TREATMENT RESPONSE;

EID: 84881476912     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28045     Document Type: Article

References (27)

1. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008; 299: 1914-1921.
2. Peiffert D, Tournier-Rangeard L, Gérard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012; 30: 1941-1948.
3. Sebag-Montefiore D, James R, Meadows H, et al. The pattern and timing of disease recurrence in squamous cancer of the anus: Mature results from the NCRI ACT II trial [Abstract]. J Clin Oncol. 2012; 30 (suppl 15): Abstract 4029.
4. Karamouzis MV, Grandis JR, Argiris A,. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA. 2007; 298: 70-82.
5. Paliga A, Onerheim R, Gologan A, et al. EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? Br J Cancer. 2012; 107: 1864-1868.
6. Mendelsohn J, Baselga J,. The EGF receptor family as targets for cancer therapy. Oncogene. 2000; 19: 6550-6565.
7. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000; 18: 904-914.
8. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001; 19: 3234-3243.
9. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009; 373: 1525-1531.
10. Van Custen E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360: 1408-1417.
11. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010; 11: 21-28.
12. Ajani JA, Winter KA, Gunderson LL, et al. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol. 2009; 27: 1116-1121.
13. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
14. Olivatto LO, Cabral V, Rosa A, et al. Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results. Int J Radiat Oncol Biol Phys. 2011; 79: 490-495.
15. Liu L, Cao Y, Tan A, et al. Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials. Cancer Chemother.Pharmacol. 2010; 65: 849-861.
16. Deutsch E, Lemanski C, Paris E, et al. Cetuximab plus radio-chemotherapy in locally advanced anal cancer: Interim results of the French multicenter phase II trial ACCORD16 [Abstract]. J Clin Oncol. 2011; 29 (suppl 15): Abstract 4098.
17. Garg M, Lee JY, Kachnic LA, et al. Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results [Abstract]. J Clin Oncol. 2012; 30 (suppl 15): Abstract 4030.
18. Moore KN, Sill MW, Miller DS, et al. A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. Gynecol Oncol. 2012; 27: 456-461.
19. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000; 60: 2926-2935.
20. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 2001; 71: 1459-1465.
21. Petrelli F, Cabiddu M, Borgonovo K, et al. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol. 2012; 23: 1672-1679.
22. Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol. 2011; 29: 1757-1764.
23. Moore RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011; 29: 3466-3473.
24. Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007; 110: 2339-2346.
25. Mandala M, Clerici M, Corradino I, et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'. Ann Oncol. 2012; 23: 1416-1421.
26. Nogueira-Rodrigues A, Carmo CC, Viegas C, et al. Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer. Clin Cancer Res. 2008; 14: 6324-6329.
27. Kachnic LA, Winter K, Myerson R, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013; 86: 27-33.